Víctor Manuel Cortés Beltrán

Dr. Víctor Manuel Cortés Beltrán

Pediatrics, Hospital Infantil de México Federico Gómez, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
SMSharon Morales-Montes
Sharon Morales-Montes
MMMichelle Maldonado-Alvarado
Michelle Maldonado-Alvarado
JMJorge A. Martin-Trejo
Jorge A. Martin-Trejo
SASalvador Atilano-Miguel
Salvador Atilano-Miguel
IDIsrael Domínguez-Calderón
Israel Domínguez-Calderón
Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and during 6 weeks of post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω-3VDCa group (100 mg/kg/d LCPUFAs-ω3 + 4000 IU vitamin D + 1000 mg calcium) or the VDCa group (4000 IU vitamin D + 1000 mg calcium) for 6 weeks. Blood samples were collected to determine 25(OH)D, PTH, ICTP, and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 weeks, and 12 weeks after supplementation. The 25(OH)D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p < 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p = 0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω-3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p = 0.024). Conclusions: Combined omega-3 and 4000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.

2 January 2025
Verified
Journal Article
Open access
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
SASalvador Atilano-Miguel
Salvador Atilano-Miguel
Víctor Manuel Cortés BeltránVíctor Manuel Cortés Beltrán
Víctor Manuel Cortés Beltrán
SMSharon Berenice Morales-Montes
Sharon Berenice Morales-Montes
JMJorge Alfonso Martín-Trejo
Jorge Alfonso Martín-Trejo
JDJuan Manuel Domínguez-Salgado
Juan Manuel Domínguez-Salgado
La 25 hidroxivitamina D (25(OH)D) desempeña un papel fundamental en el mantenimiento de la salud ósea. El tratamiento del paciente pediátrico con leucemia linfoblástica aguda (LLA), tiene un efecto negativo sobre el metabolismo óseo. describir la frecuencia de hipovitaminosis D y los cambios en las concentraciones séricas de 25(OH)D, marcadores bioquímicos y hormonales del metabolismo óseo entre el diagnóstico y la remisión. estudio de cohorte, longitudinal, prospectivo, en pacientes pediátricos (4-17 años) con diagnóstico de LLA de novo de células B y sin tratamiento previo. Se tomó una muestra de sangre periférica para determinar las concentraciones de 25(OH)D, hormona paratiroidea (PTH), fósforo y calcio iónico. se incluyeron 40 pacientes, se presentaron 7 pérdidas durante el seguimiento, por lo que sólo se analizaron 33. El 91% de los niños presentaron hipovitaminosis D. Observamos un incremento de las concentraciones del calcio iónico con respecto a los niveles basales (1.1 mmol/L frente a 1.2 mmol/L, p = 0.002). El análisis de los Δ de las concentraciones séricas de PTH y 25(OH)D mostró una relación inversa (rho = -0.397, p = 0.024). estos hallazgos confirman una alta frecuencia de hipovitaminosis D. Niveles bajos de 25(OH)D pueden comprometer la absorción de calcio y generar un aumento compensatorio de PTH.

11 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
SMSharon Morales-Montes
Sharon Morales-Montes
MMMichelle Maldonado-Alvarado
Michelle Maldonado-Alvarado
JMJorge A. Martin-Trejo
Jorge A. Martin-Trejo
SASalvador Atilano-Miguel
Salvador Atilano-Miguel
IDIsrael Domínguez-Calderón
Israel Domínguez-Calderón
Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and 6 weeks post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω3VDCa group (100 mg/kg/d LCPUFAs-ω3+4,000 IU vitamin D+1,000 mg calcium) or the VDCa group (4,000 IU vitamin D+1,000 mg calcium) for 6 weeks. Blood samples were collected to determine vitamin D (25(OH)D), PTH, ICTP and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 and 12 weeks after supplementation. The vitamin D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p< 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p=0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p=0.024). Conclusions: Combined omega-3 and 4,000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.